Datapoint: FDA Approves TG Therapeutics’ Ukoniq

The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data suggests it may be safer than its rival PI3K inhibitors, including Gilead Sciences’ Zydelig and Bayer’s Aliqopa, and the FDA will not require a black box warning on the new drug. For the treatment of marginal zone lymphoma, Zydelig currently holds preferred formulary placement for 17% of covered lives, compared to Aliqopa’s 4%.

SOURCE: MMIT Analytics, as of 2/10/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 11

Datapoint: Kansas Rejects Medicaid Contract Challenges

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 10

Datapoint: FDA Approves Sandoz, Samsung Bioepis’ Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 9

Datapoint: FDA Approves Lilly’s New Alzheimer’s Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today